Immunotherapy Drugs Show Promise as New Treatment for Hodgkin Lymphoma
Researchers are presenting the phase 1 trial results of a new immunotherapy drug trial for patients with classical Hodgkin lymphoma at the 56th Annual Meeting of the American Society of Hematology.
The trial focused on two PD-1 inhibitors, immunotherapy drugs that allow a patient’s immune system to better focus on and attack cancer cells within the body. The researchers used pembrolizumab and nivolumab to treat patients with classical Hodgkin lymphoma whose cancer failed to respond to other traditional treatments such as chemotherapy. Both inhibitors had about a 66 percent complete or partial response to the immunotherapy treatment.
The leader of one of the drug trials and Clinical Director of the Memorial Sloan Kettering Cancer Center’s Division of Hematologic Oncology, Craig H. Moskowitz, says these new drug trials show great promise. “These results are quite extraordinary given the dire circumstances these patients were facing,” He says according to Medical News Today. “Pembrolizumab has already been approved for patients with advanced melanoma and we’re excited that the drug is producing responses in other cancer types.”
Patients with Hodgkin Lymphoma May Get Social Security Disability
The National Cancer Institute estimates about 9,100 new diagnoses of Hodgkin lymphoma in 2014, as well as about 1,180 deaths. Hodgkin lymphoma is among several cancers on the Social Security Administration’s Listing of Impairments. Patients who failed to achieve remission after treatment or who experience recurrent disease within a year of treatment may be able to qualify for Social Security disability benefits.
If you or a loved one suffer from Hodgkin lymphoma and have been unable to work and earn an income, Disability Help Group is here to help. For assistance and support for your Social Security disability claim, call today – 1-(800)-800-3332.